LONDON, May 24, 2017 /PRNewswire/ --
ZIVEREL(R) designed to protect and repair oesophageal mucosa
Norgine B.V. today announced that ZIVEREL(R) is now available in Austria, Belgium, Luxembourg and Switzerland. ZIVEREL(R) is a Class III medical device for the protective treatment of the oesophageal mucosa. ZIVEREL(R) is currently the only liquid treatment designed to protect and repair the oesophagus, offering rapid relief from the symptoms of gastro-oesophageal reflux.
(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )
Gastro-oesophageal reflux disease is prevalent worldwide, and disease burden may be increasing. It affects up to 20% of the Western population and is associated with a range of risk factors.
Peter Martin, Chief Operating Officer, Norgine said, "We are pleased to make ZIVEREL(R) available in additional countries including Austria, Belgium, Luxembourg and Switzerland. This will ensure that patients have access to this important treatment. ZIVEREL(R) protects and repairs the gastro-oesophageal mucosa and offers prolonged relief from the symptoms of this burdensome condition."
ZIVEREL(R) is an over the counter product that does not require a medical prescription. Prices are applicable per market.
ZIVEREL(R) is already available from Norgine in Spain. Further launches of ZIVEREL(R) are anticipated throughout 2017.
Norgine has the commercialisation and distribution rights for ZIVEREL(R) in Australia, Austria, Belgium, Denmark, Finland, Germany, Ireland, Luxembourg, the Netherlands, New Zealand, Norway, Spain, Sweden, Switzerland and the UK.
View the full release on http://www.norgine.com
1. ZIVEREL(R) Instructions for Use, Sept. 2016
2. J Dent [http://gut.bmj.com/search?author1=J+Dent&sortspec=date&submit=Submit ] et al. Gut2005;54:710-717 doi:10.1136/gut.2004.051821. http://gut.bmj.com/content/54/5/710.full
Norgine Media Contacts
Isabelle Jouin, T: +44-(0)-1895-453-643
Charlotte Andrews, T: +44-(0)-1895-453-607
Follow us @norgine